Despite the potential of our innovative technology is limitless, at the moment we decided to focus on 3 pathological conditions impairing human health in different contexts of our modern society, all of them are easy to detect and show fast readouts:
​
-
Muscle atrophy
​
-
Type I diabetes​
​
-
Aging
​
However in the future we aim to expand our trials number as new interested investors jump on board!
​
So keep investing in us!
​
We are aware that to run multiple pre-clinical trials is not common for a newborn start-up, however we think that the best way to validate our proprietary symbiotic therapy system, requires to test it's efficacy in multiple disease conditions.
Muscle atrophy treatment
Here we aim to use our symbiotic particles to release an improved version of Follistatin into the host bloodstream. The therapeutic agent will act as a muscle stimulating factor and increase muscle mass in the host body. This project aims to dramatically improve the healthspan in old patients and astronauts. Moreover this project could help healthy people to increase their muscle mass in a safe way, replacing dangerous drugs like anabolic steroids.
​
​
​
Type I diabetes treatment
Here we aim to use symbiotic particles to release an improved version of insulin into the host bloodstream and supply low Insulin amount to the host cells in patients of type I diabetes, replacing β-cells action. This project aims to save money and time to these patients, that will in this way stop to be "slave" of repeated external insulin injections.
Anti-aging treatment
This is the more ambitious of the three projects we commit to, here we aim to increase health parameters of old hosts by using symbiotic particles releasing a coktail of therapeutic agents into the host bloodstream. In particular, as a readout we will look at known validated biological clocks and multimorbidity measures to address an effect of our therapy in different host tissues of aged hosts, avoiding a lifespan study that will not be technically transposable to primates.
